Anthony M. Joshua
Garvan Institute of Medical Research(AU)Christian Medical College, Vellore(IN)Cancer Research UK(GB)UNSW Sydney(AU)St Vincent's Hospital(AU)St Vincent's Hospital Melbourne(AU)St Vincent's Hospital Sydney(AU)St. Vincent's University Hospital(IE)St Vincent's Clinic(AU)The Kinghorn Cancer Centre(AU)University of Glasgow(GB)Saveetha University(IN)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Radiopharmaceutical Chemistry and Applications, Cancer, Lipids, and Metabolism, Cancer Genomics and Diagnostics
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Enzalutamide in Metastatic Prostate Cancer before Chemotherapy(2014)3,003 cited
- → Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial(2014)1,753 cited
- → Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer(2019)1,551 cited
- → Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma(2016)1,053 cited
- → [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial(2021)1,014 cited